Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Xiaohan Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4638-1462; OpenAlex author ID A5037290417. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2019: 3 papers · 2020: 4 papers · 2021: 5 papers · 2022: 3 papers · 2023: 4 papers · 2024: none · 2025: 9 papers · 2026: 2 papers

Papers 30

  1. The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2026.218252↗
  2. ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117479↗
  3. Menin regulates YBX1 nucleus translocation to boost the HKDC1 transcription and affects pancreatic cancer glycolysis. Co-author DOI 10.1016/j.isci.2025.113245↗
  4. A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy. Co-author DOI 10.1016/j.stem.2025.07.008↗
  5. Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Co-author DOI 10.1016/j.surg.2024.109045↗
  6. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  7. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  8. ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer Co-author DOI 10.1101/2025.07.08.663664↗
  9. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
  10. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Co-author DOI 10.1186/s12885-025-15341-z↗
  11. A mitochondria-related gene-based signature predicts pancreatic ductal adenocarcinoma clinical outcome and revealed CAMK2A/THEM4 regulates progression phenotyp… Co-author DOI 10.1186/s12967-025-07456-5↗
  12. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101162↗
  13. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  14. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
  15. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  16. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  17. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Co-author DOI 10.1038/s41467-022-29857-6↗
  18. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Co-author DOI 10.1186/s12916-022-02647-z↗
  19. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1002/ctm2.520↗
  20. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08380-9↗
  21. Which Factors Are Associated with Positive Resection Margin in Pancreatic Ductal Adenocarcinoma for different surgical procedures? Results Based on a Standard … Co-author DOI 10.21203/rs.3.rs-111309/v2↗
  22. Risk Factors of Positive Resection Margin Differ in Pancreaticoduodenectomy and Distal Pancreatosplenectomy For Pancreatic Ductal Adenocarcinoma: A Study Based… Co-author DOI 10.21203/rs.3.rs-963631/v1↗
  23. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. First author DOI 10.3389/fonc.2021.717989↗
  24. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for… Co-author DOI 10.1016/j.surg.2020.02.013↗
  25. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. First author DOI 10.1038/s41416-019-0704-2↗
  26. Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evalua… Co-author DOI 10.3389/fonc.2020.01472↗
  27. [Practice and challenge of precision medicine for pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2020.01.009↗
  28. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. Co-author DOI 10.1096/fj.201800617r↗
  29. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: stu… Co-author DOI 10.1186/s13014-019-1254-8↗
  30. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2019.11.009↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 24 shared papers, 2019–2026 · strength 3.58
  2. Shiwei Guo · 24 shared papers, 2019–2026 · strength 3.43
  3. Suizhi Gao · 23 shared papers, 2019–2026 · strength 3.22
  4. Kailian Zheng · 14 shared papers, 2019–2026 · strength 2.35
  5. Xiaoyi Yin · 13 shared papers, 2021–2026 · strength 2.26
  6. Xiongfei Xu · 10 shared papers, 2020–2026 · strength 1.53
  7. Yunguang Li · 7 shared papers, 2022–2026 · strength 1.20
  8. Guoxiao Zhang · 8 shared papers, 2021–2025 · strength 1.17
  9. Lingyu Zhu · 6 shared papers, 2023–2026 · strength 1.05
  10. Shuo Shen · 8 shared papers, 2019–2023 · strength 1.01
  11. Dong Gao · 6 shared papers, 2022–2025 · strength 1.00
  12. Bo Li · 7 shared papers, 2020–2023 · strength 0.84
  13. Meilong Shi · 4 shared papers, 2025 · strength 0.77
  14. Yehan Zhang · 4 shared papers, 2022–2026 · strength 0.65
  15. Gang Li · 5 shared papers, 2021–2025 · strength 0.64
  16. Bin Song · 4 shared papers, 2021–2025 · strength 0.58
  17. Zhuo Shao · 5 shared papers, 2019–2023 · strength 0.52
  18. Chenming Ni · 3 shared papers, 2021–2025 · strength 0.50
  19. Huan Wang · 2 shared papers, 2026 · strength 0.47
  20. Jing Shen · 4 shared papers, 2019–2021 · strength 0.41
  21. Zhendong Fu · 2 shared papers, 2025 · strength 0.40
  22. Tianlin He · 2 shared papers, 2022–2025 · strength 0.37
  23. Gang Y Jin · 2 shared papers, 2023–2025 · strength 0.37
  24. Hui Jiang · 3 shared papers, 2019–2023 · strength 0.36
  25. Gang Jin · 2 shared papers, 2022–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.